samedan logo
 
 
spacer
home > ict > Autumn 2020
PUBLICATIONS

International Clinical Trials

ict
Autumn 2020

   
Text
PDF
bullet
Features
PCI Pharma Services’ Game-Changing Digital Platform

To manage clinical trials from start to finish, you need real-time visibility throughout your clinical and commercial supply chain. Introducing pci | bridge, a transformational platform to ease your clinical trialling processes.
 
view
download pdf
bullet
Patient Engagement
The Colours of Change

Chris Wells at Illingworth Research Group

COVID-19 has been wreaking unrest across the globe, but it is hoped that when the storm passes, that disruption may give way to positive innovation.
 
view
download pdf
Engaging the Crowds

Peter Schueler at ICON plc

Patient registries should be attractive to potential patients, but engagement, support, and advocacy are lacking from these networks. Could this be causing a failure to adhere during clinical trials?
 
view
download pdf
Direct-to-Patient Trials – Improving Patient Engagement

Sarah Halmrast at CSM

Patient-centricity has become the essential element of any trial, as the pandemic has changed a lot of the ways research was conducted.
 
view
download pdf
Clinical Trial Innovation: More Important Now Than Ever

Elizabeth Gargill at BBK Worldwide

Healthcare consumers are desperate for more convenient and cost-effective solutions to trialling that both embrace them as individuals and create a positive experience for them.
 
view
download pdf


The Clinical Development Plan – The Importance of Getting it Right

Barry Drees and Julia Forjanic Klapproth at Trilogy Writing & Consulting

A CDP can ensure that your trial goes smoothly, aiding future research, subsequent trial phases, and speeding up regulatory processes.
 
view
download pdf
Accelerating Processes and Enhancing Compliance with Pharmacovigilance Automation

Dr John Price at Arriello

Enhancing pharmacovigilance data is an element of trial innovation that many do not consider. The underappreciated function can benefit many aspects of trials if properly prioritised.
 
view
download pdf
Can You Still Work With Empathy When You Work From Home?

Ross Downes at NIHR

While technology and innovation have been an essential aspect of life under lockdown, has our screen-centric existance deprived us of key communication elements?
 
view
download pdf
COVID-19 Exposes Untapped Potential in the EU’s Clinical Trial Industry

Angela La Ronde at Greenphire

Sponsors have had to step up to remote trialling during the pandemic, and with this shift came hope that the changes will last, and our technological forward-thinking will continue.
 
view
download pdf
Modernisation Movement

Anna Argyris at Veeva Systems

In an interview with Anna Argyris, EPC questions how modernising site operations will change the future landscape of clinical trials, and reduce the burden for patients.
 
view
download pdf
bullet
Cloud-Based CTMS
Using Technology to Streamline Clinical Data Management

Jeff Rogers at Crucial Data Solutions

Trials are taking longer to execute, and teams are being overwhelmed by data. Centralising data and embracing technology can ease the burden on study teams, leaving them more time to focus on their research.
 
view
download pdf
Taking a Fresh Look at CTMSs as an Integral Part of Managing Clinical Trials

Daljit Cheema at PHARMASEAL

Technology has been forced to evolve rapidly during this pandemic, but there is still work to be done. CTMSs are still due for an overhaul and a cloud-based solution may offer a more agile and integrated platform.
 
view
download pdf
Beyond the Data-Hungry Beast

Sheila Rocchio at eClinical Solutions

‘Speed’ is the word on everyone’s lips when it comes to data – faster, smarter, more agile – but these demands are dependent on the adoption of cloud-based CTMS, a process that has been expedited by the pandemic.
 
view
download pdf
bullet
AI and Machine Learning
Improving Clinical Trial Outcomes Using AI and Automation

Nagaraja Srivatsan at IQVIA

Saving time in trials shouldn’t come at the cost of patients. By incorporating digital technologies, sponsors can focus on patient experience.
 
view
download pdf
A Smart Approach to AI

Vesna Prchkovska and Paulo Rodrigues at QMENTA

Researchers would rather spend their time discovering insights, letting powerful software solutions manage the medical imaging workflow and manipulating and administrating data.
 
view
download pdf
The Progress of Real-World Data and Artificial Intelligence

Rob DiCicco at IBM Watson Health

Drug development requires collaboration to reach its full potential. By adopting AI, data don’t have to be an obstacle to this.
 
view
download pdf
Streamlining Data Management in Clinical Trials

Jennifer Bradford at PHASTAR

In order to maintain quality, clinical teams can spend hundreds of hours cleaning and managing data when this time is better spent in research.
 
view
download pdf
Swimming in Data

Kristin Mauri and Rhonda Roberts at Remarque Systems

The intelligent insights from AI help craft stories from data, aiding every aspect of clinical trials, from enrolment to reporting, so why aren’t these tools being utilised?
 
view
download pdf
bullet
Therapeutic Focus: Neurology
The Psychedelic Renaissance: Psilocybin Study Design Challenges
 
Charles Raison at Usona Institute

Psychedelics were once a highly excluded aspect of pharmaceutical research, and despite the effectiveness of treatments, there are still some social challenges to overcome.
 
view
download pdf
Remote Measures

Shani McCoy at Berkshire Healthcare Foundation Trust (NHS)

The pandemic has meant that many trials have had to halt their research. However, for some of the more vulnerable members of society, the trials are an essential part of their lives, and have had to carry on with great difficulty.
 
view
download pdf
Battling Depression: From Clinical Development Strategies to Patient Perspectives

Dr Thomas Thompson, Miaesha Campbell, Jill Adkins, and Joan Gushue at Medpace

Depression is a serious mental disorder affecting millions of people across the world. However, finding an effective treatment is a challenge with no ‘one size fits all’ solution.
 
view
download pdf
Non-Invasive Novel Biomarkers to Predict Alzheimer’s Risk

Simon Samaan at Laboratoire Cerba and Jérôme Sallette at Cerba HealthCare

Alzheimer’s research has been a focus of healthcare companies in recent years. While there remains no cure for the disease, biomarkers could hold the key to unlocking our understanding.
 
view
download pdf
   
spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement